Merkel Cell Carcinoma (MCC) - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

Merkel Cell Carcinoma (MCC) Emerging Therapy and TPP Insights

Thelansis's "Merkel Cell Carcinoma (MCC) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Merkel Cell Carcinoma (MCC) Overview

Merkel Cell Carcinoma (MCC) is an aggressive neuroendocrine skin malignancy arising from mechanoreceptor cells, heavily linked to the Merkel cell polyomavirus (MCPyV) and cumulative UV-induced damage. It typically manifests as a fast-growing, painless, violaceous nodule on sun-exposed sites in elderly or immunocompromised individuals. Diagnosis relies on immunohistochemical profiling showing characteristic dot-like perinuclear cytokeratin 20 (CK20) and synaptophysin staining. Under 2026 clinical guidelines, if initial diagnosis is made via limited core biopsy, capturing additional tumor tissue prior to treatment is mandatory to run necessary molecular baselines. Localized disease is treated with wide local excision, Mohs micrographic surgery, or single-modality hypofractionated radiation for inoperable candidates, paired with sentinel lymph node biopsy to detect microscopic regional spread. For advanced or metastatic MCC, immune checkpoint inhibitors-including avelumab, pembrolizumab, and retifanlimab-serve as the first-line standard. If a patient develops resistance to PD-1/PD-L1 monotherapy, advanced algorithms dictate escalating to dual-agent ipilimumab and nivolumab. Furthermore, surveillance has evolved significantly past conventional imaging alone; routine long-term follow-up now systematically integrates serological polyomavirus antibody tracking and circulating tumor DNA (ctDNA) liquid assays to detect molecular recurrence long before macroscopic lesions appear.

Key Highlights

• In Germany, diagnosed Merkel Cell Carcinoma (MCC) cases are projected to increase from 315 in 2025 to 335 by 2035.
• MCC is a rare and aggressive neuroendocrine skin cancer associated with a high risk of recurrence and metastasis.
• Despite advances in immunotherapy, patients with advanced or treatment-refractory disease continue to face poor clinical outcomes.
• Significant unmet need remains for therapies capable of improving long-term survival and durable disease control.

Market Overview

• The Germany MCC market is projected to grow from $180M in 2025 to $360M by 2035.
• Market growth is driven by:
• Increasing adoption of immune checkpoint inhibitors
• Ongoing development of novel immuno-oncology therapies
• Future growth will depend on therapies capable of delivering durable responses and overcoming treatment resistance.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Merck Sharp & Dohme LLC
• Incyte Corporation
• Fujifilm Pharmaceuticals U.S.A., Inc.
• Replimune, Inc.
• Phio Pharmaceuticals Inc.
• Sotio Biotech Inc.
• Kupando GmbH
• AstraZeneca
• Checkpoint Therapeutics, Inc.
• ImmunityBio, Inc.
• KaliVir Immunotherapeutics
• Neonc Technologies, Inc.
• SystImmune Inc.
• Medicenna Therapeutics, Inc.
• Sensei Biotherapeutics, Inc.